-
Leupeptin: Protease Workflow and Troubleshooting
2026-08-19
Leupeptin enables controlled, reversible suppression of serine and cysteine proteases across biochemical, viral, autophagy, and protein degradation workflows. This guide translates a metabolite-binding assay framework into practical inhibitor controls, with fresh-solution handling, orthogonal readouts, and troubleshooting strategies for reproducible results.
-
RepSox: An ALK5 Framework for hiPSC Studies
2026-08-19
RepSox is a potent and selective ALK5 inhibitor for dissecting TGF-β signaling in stem-cell experiments. This article distinguishes mechanistic pathway testing from platelet-production optimization and translates recent hiPSC findings into practical assay decisions.
-
Hexa His Tag Peptide: Clean Elution by Design
2026-08-18
Hexa His tag peptide enables selective, antibody-compatible release of His-tagged proteins from immunoprecipitation workflows. This article explains its competitive mechanism, distinguishes epitope elution from metal-affinity purification, and applies insights from recent CARMIL membrane biology to assay design.
-
GSTM5 Links Genomic Instability to PLK1 Sensitivity
2026-08-18
This study combines multi-omics Mendelian randomization with breast cancer datasets and experimental validation to prioritize GSTM5 as a genomic stability-related gene. The findings connect GSTM5 loss with impaired DNA repair and increased sensitivity to PLK1 inhibition, supporting a biomarker-informed therapeutic hypothesis rather than an established clinical treatment strategy.
-
E-64 for Cathepsin Assays in Lymphoma Research
2026-08-17
E-64 enables mechanistic cysteine protease inhibition while exposing an important assay-design challenge: broad active-site blockade is not the same as selective cathepsin S suppression. This article translates lymphoma antigen-processing research into practical decisions for biochemical, cellular, and immune-function assays.
-
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)
2026-08-17
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit protein degradation during extraction and protease-sensitive assays while avoiding EDTA-mediated divalent-cation chelation. It is suitable for workflows such as Western blotting, co-immunoprecipitation, phosphorylation analysis, and enzyme assays, but not for experiments that specifically require EDTA.
-
Protease Inhibitor Cocktail: Assay Reliability
2026-08-16
This scenario-based guide explains how Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO), SKU K1008, can protect protein endpoints associated with cell viability, proliferation, and cytotoxicity studies. It covers compatibility, dilution, interpretation, and practical criteria for selecting a reliable protein extraction protease inhibitor.
-
SLC2A5 Fructose Metabolism in Primary CNS Lymphoma
2026-08-15
This study uses single-cell RNA and B-cell receptor profiling to show how glucose-poor, hypoxic conditions in primary central nervous system lymphoma reshape tumor and microenvironment metabolism. Its central finding is that SLC2A5-mediated fructose uptake represents a functional vulnerability in lymphoma cells and tumor-supportive macrophages, with inhibition suppressing tumor growth in cellular and animal models.
-
Temozolomide Workflows for Glioma DNA-Damage Studies
2026-08-14
Temozolomide (SKU B1399) provides a practical way to model alkylation-driven DNA damage, growth inhibition, and treatment response in glioma and other cancer systems. This guide connects reliable DMSO handling with ATRX-aware combination experiments, dose-response design, and troubleshooting for more interpretable results.
-
Protease Inhibitor Cocktail EDTA-Free: K1007 Guide
2026-08-14
The Protease Inhibitor Cocktail EDTA-Free is a 100X DMSO concentrate for reducing proteolytic degradation during protein extraction and cell-lysate preparation. Its EDTA-free design supports workflows in which added chelators could interfere with divalent-cation-sensitive enzymes, including phosphorylation analysis and kinase assays.
-
SU5416 (Semaxanib): Reliable Assay Workflows
2026-08-13
Learn how SU5416 (Semaxanib), SKU A3847, can improve the interpretation and reproducibility of endothelial proliferation, viability, and angiogenesis experiments. This scenario-driven guide covers mechanism, solvent handling, concentration selection, model limitations, and evidence-based product evaluation.
-
AEBSF.HCl in Necroptosis and Protease Assays
2026-08-13
AEBSF.HCl provides irreversible serine protease control for cell lysis, protease assays, amyloid pathway experiments, and mechanistic necroptosis studies. Its greatest value is as an orthogonal reagent that separates serine-protease background from the cathepsin-driven events identified in lysosomal membrane permeabilization.
-
KDM3A–METTL16–PDK1 Axis in TKI Resistance
2026-08-12
This study identifies a linked epigenetic and mRNA-modification mechanism that elevates PDK1 and promotes EGFR-TKI resistance and tumor development. Its findings connect KDM3A-driven chromatin remodeling with METTL16–IGF2BP1 regulation of PDK1 mRNA, providing a mechanistic framework for biomarker development and combination therapy studies.
-
IPI7–IPA1 Ubiquitination in Rice Immunity
2026-08-12
The reference study identifies the RING-finger E3 ligase IPI7 as a co-activator that enables phosphorylated IPA1 to activate WRKY45 during Magnaporthe oryzae infection. Its central innovation is showing that K29-linked polyubiquitination can regulate transcription-factor activity without destabilizing the substrate, thereby separating immune activation from IPA1-dependent yield traits.
-
Chlorpromazine: A Perturbation Tool for Nanomedicine
2026-08-11
Chlorpromazine hydrochloride offers a pharmacological lens for interpreting heterogeneous hepatic nanoparticle uptake. This article connects dopamine receptor signaling with the size- and PEG-dependent findings of a 2026 ACS Nano study while defining practical assay controls and cross-domain limitations.